Mineralocorticoid receptor antagonists and the metabolic syndrome

Amir Tirosh, Rajesh Garg, Gail K. Adler

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations

Abstract

Key components of the metabolic syndrome (MetS), ie, obesity and insulin resistance, are associated with increased aldosterone production and mineralocorticoid receptor (MR) activation. Both MetS and hyperaldosteronism are proinflammatory and pro-oxidative states associated with cardiovascular disease. This review discusses emerging data that MR activation may contribute to abnormalities seen in MetS. In view of these data, MR antagonists may be beneficial in MetS, not only by controlling hypertension but also by reversing inflammation, oxidative stress, and defective insulin signaling at the cellular-molecular level. Clinical trials have demonstrated benefits of MR antagonists in heart failure, hypertension, and diabetic nephropathy, but additional trials are needed to demonstrate the clinical significance of MR blockade in MetS.

Original languageEnglish (US)
Pages (from-to)252-257
Number of pages6
JournalCurrent Hypertension Reports
Volume12
Issue number4
DOIs
StatePublished - Aug 2010
Externally publishedYes

Keywords

  • Aldosterone
  • Eplerenone
  • Insulin resistance
  • Mineralocorticoid receptor
  • Obesity
  • Spironolactone

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Mineralocorticoid receptor antagonists and the metabolic syndrome'. Together they form a unique fingerprint.

Cite this